Does Mounjaro cause anxiety and depression? What the data shows

What did @adonadio84 actually say?

The creator describes collapsing twice while driving, then developing severe panic attacks and agoraphobia within the first few doses of tirzepatide. After stopping, they report four months of debilitating symptoms, including dizziness, visual tracking issues, and neck pain, followed by gradual recovery. Sixteen months out, they're "about 98 percent" back to themselves. They call out prescribers for dismissing these reports and cite unspecified studies on GLP-1 mental health effects, pancreatitis, gallbladder, and liver injuries.

They also advise viewers who are struggling to get on psychiatric medication if they need it, and describe their own recovery as largely medication-free, relying on behavioral self-exposure to manage agoraphobia.

Does the science back this up?

Partly, yes. GLP-1 receptor agonists do have documented cardiovascular and vasovagal effects that can cause dizziness and syncope. The psychiatric picture is more complicated, and the creator gets some of it right without fully understanding why.

Tirzepatide and other GLP-1 agonists activate receptors in the gut-brain axis, including areas involved in anxiety regulation. A 2023 FDA pharmacovigilance review flagged suicidal ideation reports for semaglutide and liraglutide, though a subsequent EMA analysis found no confirmed causal link. Separate from that, panic disorder triggered by a serious somatic event (like collapsing at the wheel) is a well-recognized clinical phenomenon. Cardiophobia and health anxiety following a vasovagal or hypoglycemic-type episode can produce exactly the symptom cluster this creator describes: agoraphobia, driving avoidance, hypervigilance to bodily sensations. That does not mean Mounjaro directly caused the panic disorder, it means the collapse likely triggered it.

On the liver, gallbladder, and pancreatitis claims: acute pancreatitis risk with GLP-1 agonists is real but low. A 2022 meta-analysis by Tkáč et al. in Diabetes Care found no significant increase in pancreatitis incidence across major trials. Gallbladder disease, however, is a recognized risk. Rapid weight loss itself elevates gallstone risk, and the FDA label for tirzepatide includes a warning. Acute liver injury reports are rare and largely case-level, not established in controlled trials.

What did they get wrong (or right)?

They got the lived experience right. The symptom pattern is plausible and consistent with what other patients have reported. The support group data point, going from hundreds to thousands of members reporting similar experiences, is not a clinical study, but it is a signal worth taking seriously.

What they get wrong is causation. Attributing the panic disorder directly and solely to Mounjaro is an overreach. A vasovagal collapse while driving is a genuinely terrifying event. Post-traumatic health anxiety following a driving collapse is a documented clinical trajectory entirely independent of what caused the collapse. The creator had self-described baseline anxiety before starting the drug. Disentangling drug effect from psychological sequelae of a scary physical event is not something a TikTok video can do.

Their claim that providers "don't have a lot of history" with these medications and are gaslighting patients is partially fair. Psychiatric side effect reporting in GLP-1 trials has historically been thin. But "gaslighting" implies intentional deception, which is a different claim than "insufficient training," and conflating the two is not useful to patients trying to navigate their care.

Their recovery approach, gradual behavioral exposure to feared situations, is exactly what evidence-based treatment for agoraphobia looks like. That part deserves credit.

What should you actually know?

If you're on a GLP-1 medication and develop new or worsening anxiety, panic attacks, or agoraphobia, tell your prescriber. Do not just stop the medication without medical supervision, because abrupt discontinuation carries its own risks. The FDA does maintain a MedWatch database for adverse event reports, and your report matters.

The psychiatric side effect picture for tirzepatide specifically is still being studied. Semaglutide has more long-term data. Neither has a clean evidence base confirming or ruling out a direct anxiogenic effect at this point. A 2024 observational study by McIntyre et al. in The Lancet Psychiatry found GLP-1 agonists were associated with reduced depression and anxiety scores in a large cohort, which complicates the story considerably.

Collapsing while driving is a medical emergency regardless of cause. If that happens to you, stop driving and get evaluated before returning to the wheel. The cardiovascular effects of GLP-1 medications, including orthostatic hypotension and heart rate changes, are real and should be discussed with a prescriber before starting, especially if you have a history of syncope or arrhythmia.

If panic attacks or agoraphobia develop for any reason, they are treatable. CBT with exposure response prevention has the strongest evidence base. Medication helps many people. The creator's reluctance to take SSRIs is understandable given their context, but their general advice to get on medication if you need it is correct.